Phentolamine 0.75% (Ryzumvi) won FDA approval for presbyopia based on the phase 3 VEGA-2 and VEGA-3 trials.

Satralizumab, a first-in-class IL-6 receptor inhibitor, was approved for adults with thyroid eye disease based on the phase 3 SatraGO program.

The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.

ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.

A real-world trial found 42.6% of patients with severe hand eczema cleared on oral alitretinoin.

AMCP Nexus 2026 brings managed care leaders to San Diego October 26-29 to tackle Medicare negotiation, drug pricing policy, AI, and patient access.

IDWeek 2026 posters describe a rule-based tool classifying about 1 in 5 patients with cUTI as outpatient-eligible and 5 clusters with varied LOS.

An international eDelphi panel of 62 dermatologists agreed on a 2-step algorithm for tapering psoriasis biologics.